Value20242025TTMSelling/general/admin expenses23.1 M22.28 M22.28 MResearch & development70.47 M74.54 M74.54 MOperating income-93.53 M-96.82 M-96.82 MNon-Operating Income, Total24.84 M-44.14 M-44.14 MInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses24.88 M-44.09 M-44.09 MUnusual income/expense-47 K-53 K-53 KPretax income-68.69 M-140.95 M-140.95 MEquity in earnings———Taxes00—Non-controlling/minority interest———After tax other income/expense———Net income before discontinued operations-68.69 M-140.95 M-140.95 MDiscontinued operations———Net income-68.69 M-140.95 M-140.95 MDilution adjustment0——Preferred dividends1.74 M——Diluted net income available to common stockholders-70.43 M-140.95 M-140.95 MBasic earnings per share (Basic EPS)-1.62-1.86-1.86Diluted earnings per share (Diluted EPS)-1.62-1.86-1.86Average basic shares outstanding43.54 M75.82 M238.38 MDiluted shares outstanding43.54 M75.82 M238.38 MEBITDA-92.85 M-95.69 M-95.69 MEBIT-93.53 M-96.82 M-96.82 MCost of revenue50 K00Other cost of goods sold———Depreciation & amortization (cash flow)677 K1.13 M1.13 M
Fractyl Health Inc
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.